{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T23:11:15Z","timestamp":1775862675093,"version":"3.50.1"},"reference-count":114,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["29030\/2017"],"award-info":[{"award-number":["29030\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/50011\/2020"],"award-info":[{"award-number":["UIDB\/50011\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/50011\/2020"],"award-info":[{"award-number":["UIDP\/50011\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Epigenetic alterations, as a cancer hallmark, are associated with cancer initiation, progression and aggressiveness. Considering, however, that these alterations are reversible, drugs that target epigenetic machinery may have an inhibitory effect upon cancer treatment. The traditional drug discovery pathway is time-consuming and expensive, and thus, new and more effective strategies are required. Drug Repurposing (DR) comprises the discovery of a new medical indication for a drug that is approved for another indication, which has been recalled, that was not accepted or failed to prove efficacy. DR presents several advantages, mainly reduced resources, absence of the initial target discovery process and the reduced time necessary for the drug to be commercially available. There are numerous old drugs that are under study as repurposed epigenetic inhibitors which have demonstrated promising results in in vitro tumor models. Herein, we summarize the DR process and explore several repurposed drugs with different epigenetic targets that constitute promising candidates for cancer treatment, highlighting their mechanisms of action.<\/jats:p>","DOI":"10.3390\/pharmaceutics12050410","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T13:23:45Z","timestamp":1588166625000},"page":"410","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Repurposing Old Drugs into New Epigenetic Inhibitors: Promising Candidates for Cancer Treatment?"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7272-7300","authenticated-orcid":false,"given":"Filipa","family":"Moreira-Silva","sequence":"first","affiliation":[{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"}]},{"given":"V\u00e2nia","family":"Camilo","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0372-2493","authenticated-orcid":false,"given":"V\u00edtor","family":"Gaspar","sequence":"additional","affiliation":[{"name":"Department of Chemistry, CICECO, University of Aveiro, Campus Universit\u00e1rio de Santiago, 3810-193 Aveiro, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2342-3765","authenticated-orcid":false,"given":"Jo\u00e3o F.","family":"Mano","sequence":"additional","affiliation":[{"name":"Department of Chemistry, CICECO, University of Aveiro, Campus Universit\u00e1rio de Santiago, 3810-193 Aveiro, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP) and Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.eururo.2011.06.035","article-title":"Epigenetics in Prostate Cancer: Biologic and Clinical Relevance","volume":"60","author":"Bastian","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/cbic.201000195","article-title":"Structure and Function of Mammalian DNA Methyltransferases","volume":"12","author":"Jurkowska","year":"2010","journal-title":"ChemBioChem"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/sj.onc.1202415","article-title":"Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer","volume":"18","author":"Millar","year":"1999","journal-title":"Oncogene"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.yexcr.2010.03.007","article-title":"Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene","volume":"316","author":"Schayek","year":"2010","journal-title":"Exp. Cell Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin Modifications and Their Function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Weichert","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1158\/1535-7163.MCT-09-0689","article-title":"SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer","volume":"9","author":"Sangthongpitag","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature04020","article-title":"LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription","volume":"437","author":"Metzger","year":"2005","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1093\/bioinformatics\/bty133","article-title":"A novel computational approach for drug repurposing using systems biology","volume":"34","author":"Peyvandipour","year":"2018","journal-title":"Bioinformatics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"654","DOI":"10.7150\/ijbs.9224","article-title":"Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs","volume":"10","author":"Shim","year":"2014","journal-title":"Int. J. Boil. Sci."},{"key":"ref_14","unstructured":"Medina-Franco, J.L. (2016). Chapter 12\u2014Drug Repurposing for Epigenetic Targets Guided by Computational Methods. Epi-Informatics, Academic Press."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/gm326","article-title":"Drug repositioning for personalized medicine","volume":"4","author":"Li","year":"2012","journal-title":"Genome Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3332\/ecancer.2014.485","article-title":"The Repurposing Drugs in Oncology (ReDO) Project","volume":"8","author":"Pantziarka","year":"2014","journal-title":"Ecancermedicalscience"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/0284186X.2013.844359","article-title":"Drug repositioning from bench to bedside: Tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer","volume":"53","author":"Nygren","year":"2013","journal-title":"Acta Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","article-title":"5-Azacytidine and 5-aza-2\u2032-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy","volume":"21","author":"Christman","year":"2002","journal-title":"Oncogene"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/carcin\/bgi206","article-title":"Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols","volume":"27","author":"Lee","year":"2005","journal-title":"Carcinogenesis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s12288-016-0770-z","article-title":"Harmine, a Novel DNA Methyltransferase 1 Inhibitor in the Leukemia Cell Line","volume":"33","author":"Oodi","year":"2017","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/art.10833","article-title":"Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling","volume":"48","author":"Deng","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_24","first-page":"1596","article-title":"Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy","volume":"9","author":"Taja","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-4-32","article-title":"Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine","volume":"4","author":"Bribiesca","year":"2006","journal-title":"J. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00280-008-0773-z","article-title":"Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression","volume":"63","author":"Song","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.18632\/oncotarget.1909","article-title":"Anti-neoplastic properties of hydralazine in prostate cancer","volume":"5","author":"Sousa","year":"2014","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1038\/onc.2013.324","article-title":"RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated Dnmt1 degradation and promoting apoptosis","volume":"33","author":"Huang","year":"2013","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"23858","DOI":"10.1074\/jbc.M113.480517","article-title":"Laccaic Acid A Is a Direct, DNA-competitive Inhibitor of DNA Methyltransferase 1*","volume":"288","author":"Fagan","year":"2013","journal-title":"J. Boil. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bbrc.2007.08.005","article-title":"Mahanine reverses an epigenetically silenced tumor suppressor gene RASSF1A in human prostate cancer cells","volume":"362","author":"Jagadeesh","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1476-4598-12-99","article-title":"Mahanine restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in prostate cancer cells","volume":"12","author":"Agarwal","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/CAD.0b013e3282a215e9","article-title":"Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells","volume":"18","author":"Lin","year":"2007","journal-title":"Anti-Cancer Drugs"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1158\/1535-7163.MCT-10-0609","article-title":"Nanaomycin A Selectively Inhibits DNMT3B and Reactivates Silenced Tumor Suppressor Genes in Human Cancer Cells","volume":"9","author":"Kuck","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"76898","DOI":"10.18632\/oncotarget.20176","article-title":"DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt\u2019s lymphoma","volume":"8","author":"Poole","year":"2017","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/cmdc.201300555","article-title":"Toward Drug Repurposing in Epigenetics: Olsalazine as a Hypomethylating Compound Active in a Cellular Context","volume":"9","author":"Tran","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_36","first-page":"8611","article-title":"Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide","volume":"61","author":"Lin","year":"2001","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3892\/or_00000590","article-title":"Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells","volume":"22","author":"Jablons","year":"2009","journal-title":"Oncol. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"40749","DOI":"10.1074\/jbc.M505593200","article-title":"Procainamide Is a Specific Inhibitor of DNA Methyltransferase 1","volume":"280","author":"Lee","year":"2005","journal-title":"J. Boil. Chem."},{"key":"ref_39","first-page":"4984","article-title":"Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells","volume":"63","author":"Fraga","year":"2003","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12072-007-9014-5","article-title":"Procaine inhibits the proliferation and DNA methylation in human hepatoma cells","volume":"1","author":"Tada","year":"2007","journal-title":"Hepatol. Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1002\/jcb.26407","article-title":"Procaine is a specific DNA methylation inhibitor with anti-tumor effect for human gastric cancer","volume":"119","author":"Li","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1177271919846454","DOI":"10.1177\/1177271919846454","article-title":"Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia","volume":"14","author":"Wong","year":"2019","journal-title":"Biomark. Insights"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1479-5876-4-10","article-title":"Hydralazine target: From blood vessels to the epigenome","volume":"4","author":"Arce","year":"2006","journal-title":"J. Transl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2174\/1570180054038413","article-title":"Computational Studies of 1-Hydrazinophthalazine (Hydralazine) as Antineoplasic Agent. Docking Studies on Methyltransferase","volume":"2","author":"Angeles","year":"2005","journal-title":"Lett. Drug Des. Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0304-3835(02)00500-1","article-title":"Apicidin, a histone deacetylase inhibitor, induces differentiation of HL-60 cells","volume":"189","author":"Hong","year":"2003","journal-title":"Cancer Lett."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1128\/MCB.01516-07","article-title":"Histone Deacetylase Inhibitor Depsipeptide Activates Silenced Genes through Decreasing both CpG and H3K9 Methylation on the Promoter","volume":"28","author":"Wu","year":"2008","journal-title":"Mol. Cell. Boil."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/CAD.0b013e328339848b","article-title":"Apicidin upregulates PHD2 prolyl hydroxylase gene expression in cervical cancer cells","volume":"21","author":"Durczak","year":"2010","journal-title":"Anti-Cancer Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cbi.2008.01.007","article-title":"Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells","volume":"172","author":"Im","year":"2008","journal-title":"Chem. Interact."},{"key":"ref_49","first-page":"111","article-title":"Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells","volume":"39","author":"Reddy","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.canlet.2012.06.017","article-title":"Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing","volume":"325","author":"Ahn","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_51","first-page":"6552","article-title":"HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth in vitro and in vivo via inhibiting HDAC8 expression","volume":"16","author":"Ahn","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Kumari, K., Keshari, S., Sengupta, D., Sabat, S.C., and Mishra, S.K. (2017). Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3863-7"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/mc.20866","article-title":"Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study","volume":"51","author":"Pandey","year":"2011","journal-title":"Mol. Carcinog."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11010-010-0651-y","article-title":"Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90","volume":"348","author":"Meng","year":"2010","journal-title":"Mol. Cell. Biochem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1016\/j.lfs.2005.01.003","article-title":"Carbamazepine is an inhibitor of histone deacetylases","volume":"76","author":"Beutler","year":"2005","journal-title":"Life Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"37230","DOI":"10.5812\/ircmj.37230","article-title":"Comparison of Anticancer Effects of Carbamazepine and Valproic Acid","volume":"18","author":"Akbarzadeh","year":"2016","journal-title":"Iran. Red Crescent Med. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"152900","DOI":"10.1016\/j.phymed.2019.152900","article-title":"Repurposing natural products as novel HDAC inhibitors by comparative analysis of gene expression profiles","volume":"59","author":"Byun","year":"2019","journal-title":"Phytomedicine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/BF02980164","article-title":"Antiproliferative effect of trichostatin A and HC-toxin in T47D human breast cancer cells","volume":"27","author":"Joung","year":"2004","journal-title":"Arch. Pharmacal Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/ijc.23295","article-title":"Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells","volume":"122","author":"Deubzer","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1021\/jo034248t","article-title":"Psammaplins from the SpongePseudoceratinapurpurea:Inhibition of Both Histone Deacetylase and DNA Methyltransferase","volume":"68","author":"Pina","year":"2003","journal-title":"J. Org. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1021\/jm2016182","article-title":"Defining the Mechanism of Action and Enzymatic Selectivity of Psammaplin A against Its Epigenetic Targets","volume":"55","author":"Baud","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbagen.2014.11.007","article-title":"Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7\/adr human breast cancer cells and xenografts","volume":"1850","author":"Kim","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2007.08.098","article-title":"A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells","volume":"108","author":"Ahn","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/emm.2007.6","article-title":"Psammaplin A is a natural prodrug that inhibits class I histone deacetylase","volume":"39","author":"Kim","year":"2007","journal-title":"Exp. Mol. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3892\/or.2011.1585","article-title":"Sodium butyrate-induced DAPK-mediated apoptosis in human gastric cancer cells","volume":"27","author":"Shin","year":"2011","journal-title":"Oncol. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Li, L., Sun, Y., Liu, J., Wu, X., Chen, L., Ma, L., and Wu, P. (2015). Histone deacetylase inhibitor sodium butyrate suppresses DNA double strand break repair induced by etoposide more effectively in MCF-7 cells than in HEK293 cells. BMC Biochem., 16.","DOI":"10.1186\/s12858-014-0030-5"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-016-0233-x","article-title":"Hypoacetylation, hypomethylation, and dephosphorylation of H2B histones and excessive histone deacetylase activity in DU-145 prostate cancer cells","volume":"9","author":"Cang","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_68","first-page":"971","article-title":"Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo","volume":"7","author":"Vigushin","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0959-8049(03)00072-8","article-title":"Histone acetylation-mediated regulation of genes in leukaemic cells","volume":"39","author":"Chambers","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.3892\/mmr.2015.3268","article-title":"Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines","volume":"11","author":"Ma","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lfs.2018.02.019","article-title":"Combinatorial strategy of epigenetic and hormonal therapies: A novel promising approach for treating advanced prostate cancer","volume":"198","author":"Motawi","year":"2018","journal-title":"Life Sci."},{"key":"ref_72","first-page":"687","article-title":"Trichostatin A inhibits proliferation of PC3 prostate cancer cells by disrupting the EGFR pathway","volume":"18","author":"Zhang","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1111\/jcmm.13475","article-title":"Hyper-acetylation contributes to the sensitivity of chemo-resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A","volume":"22","author":"Xu","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MPA.0000000000000982","article-title":"Histone Deacetylase Inhibition Restores Expression of Hypoxia-Inducible Protein NDRG1 in Pancreatic Cancer","volume":"47","author":"Tiffon","year":"2018","journal-title":"Pancreas"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4103\/abr.abr_91_19","article-title":"Effect of 5-aza-2\u2032-deoxycytidine in comparison to valproic acid and trichostatin a on histone deacetylase 1, dna methyltransferase 1, and cip\/kip family (p21, p27, and p57) genes expression, cell growth inhibition, and apoptosis induction in colon cancer sw480 cell line","volume":"8","author":"Kavoosi","year":"2019","journal-title":"Adv. Biomed. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biocel.2019.05.014","article-title":"Histone deacetylase inhibitors promote ATP2A3 gene expression in hepatocellular carcinoma cells: p300 as a transcriptional regulator","volume":"113","year":"2019","journal-title":"Int. J. Biochem. Cell Boil."},{"key":"ref_77","first-page":"125","article-title":"Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4","volume":"36","author":"Ahn","year":"2010","journal-title":"Int. J. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/sj.onc.1210776","article-title":"Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells","volume":"27","author":"You","year":"2007","journal-title":"Oncogene"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"19134","DOI":"10.1074\/jbc.M301580200","article-title":"Small Molecule Modulators of Histone Acetyltransferase p300","volume":"278","author":"Balasubramanyam","year":"2003","journal-title":"J. Boil. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1182\/blood-2007-10-117994","article-title":"Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kappaBalpha kinase, leading to potentiation of apoptosis","volume":"111","author":"Sung","year":"2008","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Han, H., Yang, X., Pandiyan, K., and Liang, G. (2013). Synergistic Re-Activation of Epigenetically Silenced Genes by Combinatorial Inhibition of DNMTs and LSD1 in Cancer Cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075136"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"33716","DOI":"10.1074\/jbc.M402839200","article-title":"Polyisoprenylated Benzophenone, Garcinol, a Natural Histone Acetyltransferase Inhibitor, Represses Chromatin Transcription and Alters Global Gene Expression","volume":"279","author":"Balasubramanyam","year":"2004","journal-title":"J. Boil. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Collins, H., Abdelghany, M.K., Messmer, M., Yue, B., Deeves, S.E., Kindle, K.B., Mantelingu, K., Aslam, A., Winkler, S., and Kundu, T.K. (2013). Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-37"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1476-4598-13-66","article-title":"Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo","volume":"13","author":"Sethi","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41401-019-0271-3","article-title":"Garcinol inhibits esophageal cancer metastasis by suppressing the p300 and TGF-beta1 signaling pathways","volume":"41","author":"Wang","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbrc.2013.12.144","article-title":"Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives","volume":"444","author":"Sakane","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"9352","DOI":"10.1039\/C7OB02369C","article-title":"Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues","volume":"15","author":"Jiang","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bbrc.2015.09.164","article-title":"Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo","volume":"467","author":"Wang","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"24453","DOI":"10.1074\/jbc.M109.023861","article-title":"Inhibition of Lysine Acetyltransferase KAT3B\/p300 Activity by a Naturally Occurring Hydroxynaphthoquinone, Plumbagin*","volume":"284","author":"Ravindra","year":"2009","journal-title":"J. Boil. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.18632\/oncotarget.23883","article-title":"Ribavirin as a potential therapeutic for atypical teratoid\/rhabdoid tumors","volume":"9","author":"Casaos","year":"2018","journal-title":"Oncotarget"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.bbrc.2018.10.124","article-title":"Clinically relevant concentration of anti-viral drug ribavirin selectively targets pediatric osteosarcoma and increases chemosensitivity","volume":"506","author":"Chen","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.3892\/or.2015.3816","article-title":"Ribavirin as a tri-targeted antitumor repositioned drug","volume":"33","author":"Trujillo","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/nor049","article-title":"Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors","volume":"13","author":"Singh","year":"2011","journal-title":"Neuro-Oncology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.humpath.2011.10.010","article-title":"Lysine-specific demethylase 1 (LSD1\/KDM1A\/AOF2\/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing\u2019s sarcoma, osteosarcoma, and rhabdomyosarcoma","volume":"43","author":"Machado","year":"2012","journal-title":"Hum. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.chembiol.2006.05.004","article-title":"Histone H3 Lysine 4 Demethylation Is a Target of Nonselective Antidepressive Medications","volume":"13","author":"Lee","year":"2006","journal-title":"Chem. Boil."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.febslet.2006.06.092","article-title":"Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation","volume":"580","author":"Sun","year":"2006","journal-title":"FEBS Lett."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bioorg.2019.03.027","article-title":"Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy","volume":"87","author":"Yuan","year":"2019","journal-title":"Bioorganic Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3892\/mmr.2014.2929","article-title":"Berberine targets epidermal growth factor receptor signaling to suppress prostate cancer proliferation in vitro","volume":"11","author":"Huang","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cbin.10206","article-title":"Berberine induces apoptosis in human multiple myeloma cell line U266 through hypomethylation of p53 promoter","volume":"38","author":"Qing","year":"2014","journal-title":"Cell Boil. Int."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"9542","DOI":"10.1021\/acs.jafc.6b04453","article-title":"Plant Isoquinoline Alkaloid Berberine Exhibits Chromatin Remodeling by Modulation of Histone Deacetylase To Induce Growth Arrest and Apoptosis in the A549 Cell Line","volume":"64","author":"Kalaiarasi","year":"2016","journal-title":"J. Agric. Food Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.chembiol.2007.06.007","article-title":"Parthenolide Specifically Depletes Histone Deacetylase 1 Protein and Induces Cell Death through Ataxia Telangiectasia Mutated","volume":"14","author":"Gopal","year":"2007","journal-title":"Chem. Boil."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3389\/fphar.2019.00542","article-title":"Collateral Sensitivity of Parthenolide via NF-\u03baB and HIF-\u03b1 Inhibition and Epigenetic Changes in Drug-Resistant Cancer Cell Lines","volume":"10","author":"Dawood","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1124\/jpet.108.147934","article-title":"Modulation of DNA methylation by a sesquiterpene lactone parthenolide","volume":"329","author":"Liu","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"9026","DOI":"10.18632\/oncotarget.7030","article-title":"Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations","volume":"7","author":"Hartman","year":"2016","journal-title":"Oncotarget"},{"key":"ref_105","first-page":"1377","article-title":"Resveratrol epigenetically regulates the expression of zinc finger protein 36 in nonsmall cell lung cancer cell lines","volume":"41","author":"Fudhaili","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/biof.1544","article-title":"Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21CIP1 in human breast cancer cell lines","volume":"45","author":"Chatterjee","year":"2019","journal-title":"BioFactors"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.biocel.2019.05.020","article-title":"Resveratrol up-regulates ATP2A3 gene expression in breast cancer cell lines through epigenetic mechanisms","volume":"113","year":"2019","journal-title":"Int. J. Biochem. Cell Boil."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3389\/fendo.2019.00734","article-title":"Resveratrol Reverses Retinoic Acid Resistance of Anaplastic Thyroid Cancer Cells via Demethylating CRABP2 Gene","volume":"10","author":"Liu","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tiv.2016.06.004","article-title":"Berberine acts as a putative epigenetic modulator by affecting the histone code","volume":"36","author":"Wang","year":"2016","journal-title":"Toxicol. Vitr."},{"key":"ref_110","first-page":"100","article-title":"Molecular mechanisms of parthenolide\u2019s action: Old drug with a new face","volume":"64","author":"Koprowska","year":"2010","journal-title":"Postepy Hig. Med. Dosw. (Online)"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Venturelli, S., Berger, A., B\u00f6cker, A., Busch, C., Weiland, T., Noor, S., Leischner, C., Schleicher, S., Mayer, M., and Weiss, T.S. (2013). Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS ONE, 8.","DOI":"10.1371\/annotation\/5b9a8614-1009-40ca-b90b-db817fe445c9"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"H\u00e4rm\u00e4, V., Virtanen, J., M\u00e4kel\u00e4, R., Happonen, A., Mpindi, J.-P., Knuuttila, M., Kohonen, P., L\u00f6tj\u00f6nen, J., Kallioniemi, O.-P., and Nees, M. (2010). A Comprehensive Panel of Three-Dimensional Models for Studies of Prostate Cancer Growth, Invasion and Drug Responses. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010431"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fonc.2017.00293","article-title":"High-Content Monitoring of Drug Effects in a 3D Spheroid Model","volume":"7","author":"Mittler","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Leach, D., and Buchanan, G. (2017). Stromal Androgen Receptor in Prostate Cancer Development and Progression. Cancers, 9.","DOI":"10.3390\/cancers9010010"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/5\/410\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:32:18Z","timestamp":1760362338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/5\/410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,29]]},"references-count":114,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["pharmaceutics12050410"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics12050410","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,29]]}}}